GW Pharmaceuticals announces Sativex regulatory approval in Switzerland GW Pharmaceuticals announced that it has received regulatory approval for its prescription medicine Sativex in Switzerland. A full marketing authorization has been granted by the Swissmedic authorities in the treatment of moderate to severe spasticity in Multiple Sclerosis patients who have not responded adequately to other anti-spasticity medications. Launch timing is dependent on completion of pricing and reimbursement procedures. Sativex will be commercialized in Switzerland by GW's European partner, Almirall S.A.
News For GWPH From The Last 14 Days
Check below for free stories on GWPH the last two weeks.
CNN documentary could be catalyst for GW Pharmaceuticals, says Piper Piper Jaffray believes CNN's second documentary tomorrow night on the medicinal properties of the cannabis plant could be a positive catalyst for shares of GW Pharmaceuticals. Piper notes CNN's Sanjay Gupta speaks with GW. The firm believes the show could move GW further into the medical marijuana national spotlight and it keeps an Overweight rating on the stock with a $97 price target.